Business Context and Reporting Period
Company: W.W. Grainger, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Grainger is the leading broad-line supplier of facilities maintenance products in North America, operating through three segments: Branch-based Distribution, Lab Safety, and Integrated Supply. The company utilizes a multichannel business model including 573 branches, 17 distribution centers, and various electronic channels.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Net Sales | $1,301,057 | $3,784,830 |
| Gross Profit | $479,283 | $1,386,575 |
| Gross Margin % | 36.8% | 36.6% |
| Operating Earnings | $107,444 | $315,083 |
| Operating Margin % | 8.3% | 8.3% |
| Net Earnings | $67,689 | $196,867 |
| Diluted EPS | $0.74 | $2.15 |
| Cash Flow from Operations (9mo) | $305,318 | |
| Working Capital | $1,049,539 (as of Sep 30, 2004) | |
| Total Debt | $9,485 (Long-term only; Commercial paper liquidated) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.4% in Q3 and 7.8% for the nine-month period compared to 2003, driven by an improved economy, hurricane-related demand in the Southeast, and growth across all segments.
- Profitability: Net earnings rose 19.1% year-over-year for both the quarter and the nine-month period. Operating earnings increased 13.9% in Q3 and 13.1% for the nine months.
- Margin Expansion: Gross profit margin improved to 36.8% in Q3 (from 35.4% in 2003) due to lower product costs and favorable product mix.
- Debt Reduction: Total debt as a percent of total capitalization dropped to 0.5% from 7.5% at year-end 2003. The company liquidated a cross-currency swap and paid off $140.8 million in long-term debt in Q3.
- Share Repurchases: The company repurchased 1,884,000 shares in the first nine months of 2004, compared to 474,700 shares in the same period of 2003.
Guidance, Outlook, and Risks
- Capital Expenditures: Full-year 2004 capital investment guidance was lowered to $130–$140 million (from a previous $150–$175 million range) due to delays in real estate markets and a shift toward leasing branches. Approximately $63 million was spent in the first nine months.
- Medicare Act Benefit: The company recognized a benefit from the Medicare Prescription Drug, Improvement and Modernization Act of 2003, which reduced net periodic postretirement costs by $3.6 million for 2004 and added approximately one cent to Q3 diluted EPS.
- Legal Proceedings: The EPA filed an administrative complaint seeking a $0.4 million civil penalty for alleged violations of clean-air laws regarding ozone-depleting substances. Management does not believe the resolution will be material.
- Risks: Forward-looking statements are subject to risks including higher product costs, competitive pricing pressure, litigation outcomes, and general economic conditions.
Investor Verification Checklist
- Debt Liquidity: Verify the impact of the $140.8 million debt payoff on future liquidity and the current 0.5% debt-to-capitalization ratio.
- Capital Expenditure Guidance: Confirm the revised full-year CapEx range of $130–$140 million and the rationale regarding real estate market delays.
- Medicare Subsidy Impact: Review the specific accounting treatment and future sustainability of the $3.6 million benefit from the Medicare Act subsidy.
- Segment Performance: Analyze the divergence in growth rates between Branch-based Distribution (8.6% Q3 growth) and Integrated Supply (2.0% Q3 growth).
- Legal Exposure: Monitor the status of the EPA administrative complaint regarding ozone-depleting substances.